Form 4: Cytokinetics Director John T. Henderson Sells Shares Under 10b5-1 Plan
SEC Form 4
Director John T. Henderson sold 10,562 shares of Cytokinetics Inc. common stock at $64.54 per share on April 25, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On April 25, 2024, John T. Henderson, a director of Cytokinetics Inc., sold 10,562 shares of common stock.
- The sale was executed at a price of $64.54 per share.
- The transaction was conducted under a pre-existing 10b5-1 trading plan established on September 18, 2023.
- Following the transaction, Henderson directly owns 32,070 shares of Cytokinetics Inc.
- Henderson also indirectly owns 83 shares through his spouse.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transaction is a routine sale under a pre-arranged trading plan and doesn't necessarily indicate a positive or negative outlook on the company.
Industry Context
Sales by insiders are a common occurrence and are often related to personal financial planning rather than a reflection of the company's prospects. The use of a 10b5-1 plan suggests the insider is selling shares in a pre-planned manner to avoid accusations of insider trading.
Key Dates
| Date | Description |
|---|---|
| 2023-09-18 | Date of establishment of the 10b5-1 trading plan. |
| 2024-04-25 | Date of the stock sale transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.